[Press Release – For Immediate Release]

Regent Pacific Group Limited
(Stock Code: 0575.HK)

Announces Deep Longevity's Strategic U.S. Market Entry in Q1 2026

(1 December 2025, Hong Kong) – Regent Pacific Group Limited ("**Regent Pacific**" or the "**Company**" and collectively with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that its subsidiary Deep Longevity, Inc. ("**Deep Longevity**"), a global leader in explainable AI-driven aging clocks and longevity science, today announced its planned expansion into the United States in the first quarter of 2026. This move positions the company at the centre of the world's largest and fastest-growing wellness market, currently valued at more than US$6.8 trillion.

The United States offers unmatched scale and demand for evidence-based longevity solutions. Deep Longevity's clinically validated deep aging clocks – including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge – deliver precise, multi-dimensional biological age assessments that go far beyond chronological age. These tools empower consumers, physicians, employers, and insurers with actionable, personalized insights to extend health-span and slow the aging process.

To drive rapid adoption, Deep Longevity is building a world-class U.S.-based sales organization with the first two salespersons joining on 1 January 2026. The new team will establish high-impact partnerships with longevity platforms, consumer health apps, diagnostic laboratories, wellness clinics, corporate wellness programs, insurance carriers, employers, and premium health service providers. The team will initially focus its sales efforts on the southeastern region of the U.S., including the states of Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia and West Virginia.

Deepankar Nayak, CEO of Deep Longevity, said, "Entering the U.S. is the most important milestone in Deep Longevity's journey. Our aging clocks are already trusted by leading clinics and platforms worldwide. With a dedicated American team, we are ready to bring personalized,

preventive longevity care to millions of people and capture a significant share of this $6.8 trillion market opportunity."

Deep Longevity's technology is backed by numerous peer-reviewed publications and multiple granted patents. Its multimodal aging clocks integrate blood biomarkers, epigenetics, psychology, biometrics, and soon facial imaging to provide the most comprehensive picture of biological aging available today.

-Ends-

About Deep Longevity

Deep Longevity is a wholly owned subsidiary of Regent Pacific Group Limited, developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age.

www.deeplongevity.com

About Regent Pacific Group Limited (Stock code: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders since its initial public offering in May 1997.

www.regentpac.com

This press release is distributed by LBS Communications Consulting Limited.

For media inquiries, please contact:

Joanne Chan   Tel: (852)3679 3671   Email: jchan@lbs-comm.com

The English version of this press release shall prevail in case of any discrepancy or inconsistency between the English version and its Chinese translation.